Correvio Pharma (CORV) Short Interest Ratio & Short Volume

Short interest is the volume of Correvio Pharma shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 2,120,000 shares of CORV short. 3.46% of Correvio Pharma's shares are currently sold short. Learn More on Correvio Pharma's current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.46% of Correvio Pharma's floating shares are currently sold short.

Correvio Pharma saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,120,000 shares, a decline of 8.2% from the previous total of 2,310,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Correvio Pharma currently has issued a total of 66,191,000 shares. Some of Correvio Pharma's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Correvio Pharma currently has a public float of 61,320,000 shares.

3.46% of Correvio Pharma's shares are currently sold short. Here is how the short interest of companies compare to Correvio Pharma: Procaps Group S.A. (0.12%), OptiNose, Inc. (1.68%), PyroGenesis Canada Inc. (0.14%), Aadi Bioscience, Inc. (6.58%), Actinium Pharmaceuticals, Inc. (4.54%), Eagle Pharmaceuticals, Inc. (0.46%), Marinus Pharmaceuticals, Inc. (3.95%), Allakos Inc. (0.37%), Cara Therapeutics, Inc. (1.74%), NanoViricides, Inc. (1.62%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.57 billion), Match Group Inc. ($3.08 billion), Wayfair Inc. ($2.66 billion), The Clorox Company ($2.52 billion), The Charles Schwab Corporation ($2.39 billion), DexCom, Inc. ($2.39 billion), International Flavors & Fragrances Inc. ($1.88 billion), The Kroger Co. ($1.78 billion), Snap Inc. ($1.66 billion), and Sarepta Therapeutics, Inc. ($1.63 billion). View all of the most shorted stocks.

Short selling CORV is an investing strategy that aims to generate trading profit from Correvio Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Correvio Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CORV, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CORV, twice per month. The most recent reporting period available is May, 15 2020.